How to Decide When to Move to a Systemic and Target IL-13 Versus IL-4 in AD
Dr Sarina Elmariah discusses when to recommend systemic therapy in patients with AD and if the therapy should target IL-13 or IL-4.
Date of Last Review: July 19, 2024
Document Number: VV-MED-152757
Please rate your satisfaction with the content on the following statements:
Very Dissatisfied
Dissatisfied
Neutral
Satisfied
Very Satisfied
Credibility of information
Relevance of the information to my needs
Confidence to implement the learnings in my clinical practice
Please rate your satisfaction with the content on the following statements:
Credibility of information
Relevance of the information to my needs
Confidence to implement the learnings in my clinical practice